Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06847542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Study acronym: Sightspire
StatusRecruiting
PhasePhase 3
Started2025-11-27
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

Amendment history 4 changes detected by DataLookout

2026-05-27
Primary completion pushed: 2028-09-12 → 2028-11-15
2026-05-27
Completion pushed: 2028-10-12 → 2028-11-15
2026-04-28
Trial sites expanded: 53 → 56 locations
2026-03-31
Trial sites expanded: 45 → 53 locations
Trial Details
NCT Number NCT06847542
Lead Sponsor Hoffmann-La Roche
Collaborators: Genentech, Inc.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 250 participants
Start Date 2025-11-27
Primary Completion 2028-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-21